Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Operating Leases (2019 - 2026)

Neurocrine Biosciences filings provide 7 years of Operating Leases readings, the most recent being $471.3 million for Q4 2025.

  • On a quarterly basis, Operating Leases rose 3.56% to $471.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $471.3 million, a 3.56% increase, with the full-year FY2025 number at $471.3 million, up 3.56% from a year prior.
  • Operating Leases hit $471.3 million in Q4 2025 for Neurocrine Biosciences, down from $479.7 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $479.7 million in Q3 2025 to a low of $90.4 million in Q1 2023.
  • Median Operating Leases over the past 5 years was $120.6 million (2021), compared with a mean of $222.4 million.
  • Biggest five-year swings in Operating Leases: fell 24.29% in 2023 and later soared 218.47% in 2024.
  • Neurocrine Biosciences' Operating Leases stood at $105.3 million in 2021, then fell by 11.21% to $93.5 million in 2022, then skyrocketed by 102.99% to $189.8 million in 2023, then surged by 139.78% to $455.1 million in 2024, then rose by 3.56% to $471.3 million in 2025.
  • The last three reported values for Operating Leases were $471.3 million (Q4 2025), $479.7 million (Q3 2025), and $439.1 million (Q2 2025) per Business Quant data.